|
Eyetech
Pharmaceuticals, Inc.
500
Seventh Avenue, 18th Floor
New York, New York 10018
Phone
212-997-9241
Fax 212-997-9251
http://www.eyetk.com
Chairman of the Board: John McLaughlin
Chief Executive Officer: David R. Guyer MD
Chief
Financial Officer: Glenn Sblendorio
Chief
Scientific Officer: Anthony P. Adamis, M.D.
Sr.
VP Clinical Development: Denis O'Shaughnessy, Ph.D
Sr.
VP Marketing & Sales: Arda Ural MSc, MBA
| Founded: |
February
2000 |
| |
|
| Financing:
|
Series
C Preferred: US $108.5 Million (July, 2001) |
| |
Principal
Investors:
JP
Morgan Partners, LLC
BB
Biotech
MPM
Capital
Alta
Partners
Schroeder
Ventures Life
Sciences
Merrill
Lynch Ventures, LLC
|
| |
Series
B Preferred: US $34 Million
(April, 2000) |
|
Eyetech Pharmaceuticals, Inc. is devoted to developing
and commercializing novel proprietary drugs to reduce and
prevent vision loss caused by ophthalmic diseases. Founded
in early 2000, the initial focus is on the back of the eye,
an area of significant unmet medical need.
Eyetech has obtained worldwide rights from Gilead Sciences
to develop and commercialize the anti-VEGF aptamer (Macugen™ (pegaptanib sodium)),
an anti-angiogenic drug. Macugen™ (pegaptanib sodium) is targeted for the treatment
of age-related macular degeneration (AMD) and diabetic macular
edema (DME). Age-related macular degeneration is one of the
most common causes of vision impairment in people over the
age of 50 in the United States and other western countries.
DME is the leading cause of vision loss in diabetics.
|
 |
|
Eyetech's lead product, Macugen™
(pegaptanib sodium),
is
an anti-VEGF aptamer. The aptamer was discovered using SELEX
process. Macugen™ (pegaptanib sodium) is an oligonucleotide
that acts like a high affinity antibody to VEGF.This anti-VEGF
aptamer blocks blood vessel growth and inhibits neovascularization
in pre-clinical models.
|
|
Macugen™
(pegaptanib sodium) is from
the aptamer class of compounds, and may inhibit angiogenesis
by acting like an antibody and blocking a chemical called
vascular endothelial growth factor (VEGF), potentially preventing
the growth of ocular blood vessels and/or vessel leakage in
the eye. If proven to prevent leakage from blood vessels and/or
the growth of new blood vessels, Macugen™ (pegaptanib
sodium) may potentially represent a potent combination
for the treatment of AMD and DME.
Illnesses
Addressed: Diseases of the retina, specifically age-related
macular degeneration (AMD) and diabetic macular edema (DME).
|
|
In November 2000, Eyetech entered into a research support
agreement with the Massachusetts Eye and Ear Infirmary (MEEI),
the teaching affiliate of Harvard Medical School. Pursuant
to the Agreement, Eyetech has exclusive rights of negotiation
with respect to research developments originating in the lab
of the Retinal Research Group at MEEI.
|
|
Eyetech
has licensed worldwide rights to Macugen™ (pegaptanib sodium) from Gilead Sciences.
|
|
|
Pdf
Format
